|
|
 |
|
Viewing report
|
|
|
|
Emerging Pharmaceutical Markets: Growth Opportunities, Changing Healthcare Dynamics and Regulatory Trends
Business Insights, Aug 2007, Pages: 270
The growth of emerging pharmaceutical markets remains impressively buoyant, having attained a 14.7% value increase over the 2005-06 period, a substantially greater rate than those witnessed within the developed markets of the EU and US. Although emergent markets proffer access to sizeable patient populations, significant barriers to entry continue to exist. For Western players, successful entry is contingent upon a comprehensive understanding of market dynamics, including differentiated growth prospects, socio-political structures and local market environments.
Sustainable success can be derived from maintaining an acute awareness and timely exploitation of opportunities and threats that arise from healthcare financing systems, epidemiology and therapeutic forecasts, pricing and reimbursement policies, licensing sales trends, IP protection and leading player dynamics. Emerging Pharmaceutical Markets is a new report, examining the external, regulatory and competitive environments of emergent markets in 24 countries across Asia, Central and Eastern Europe, and Latin America. The impact of licensing laws and reforms upon market penetration potential within these countries is assessed, and the trends that influence market opportunities are profiled.
This report will also provide detailed analyses and forecasts to establish the future direction of emergent markets, and identify the key strategies necessary in securing successful market entry and sustainable growth. Use this report to evaluate the performance of pharma sales in 24 emergent countries, identify the key external and regulatory factors shaping these markets and assess the strategies of leading competitors...
Some key findings from this report...
-Emerging pharma markets experienced a relatively strong CAGR
of 16% between 2002-06, compared to the EU5 or US equivalents of
12.9% and 7.7% respectively. The catalysts for this growth include
increased access to medicines, expanded healthcare formulatory
listings and the availability of cheaper generics.
-The average percentage of GDP spent on healthcare in the
combined emergent markets was 5.9%, or $18.1bn in 2004, as
compared to 9.2%, or $919.3mn, for the EU5 during the same period.
-Latin America offers significant sales potential for ACE Inhibitors
and analgesics, because of a high frequency of cardiovascular
disorders across the region. Hypercholesterolemia, Latin America’s
most common cardiovascular risk factor, had an estimated prevalence
rate of 32% in 2004, and is forecast to rise to 34.6% by 2010.
- The five main therapeutic areas within emergent markets
constituted 66.7% of total sales, or $49.6bn, in 2006, with
alimentary, metabolic and anti-infective products leading the market.
Systemic antibiotics and antacids continue to dominate growth.
-China has the largest healthcare spend of all emerging Asian
economies, totalling $74.2bn in 2003. Korea and India are the next
largest, with $41.1bn and $27.7bn respectively.
Key issues examined in this report...
-The investment dilemma. Despite considerable challenges, emergent
pharma markets will experience continued growth. Accession to the
WTO has strengthened this trend, with stricter patent regimes now being
developed and enforced.
-Cancer market potential. High levels of unmet need and weak
capabilities in cancer treatment therapies have resulted in this
therapeutic area having the strongest prospects for growth. Cyostatics
and immunomodulatory agents hold the greatest demand potential.
-Generic vs. branded products. Government endorsed production and a
strong foundation for generics manufacturing have increased the use of
generics in mainstream indications. As a result, it is unlikely that branded
products can dominate emergent markets over the forecast period.
-Successful entry strategies. Although a number of entry strategies exist
for MNC’s, these must be tailored according to a number of factors
including organisational capability, portfolio development, governmental
procurement priorities and barriers to entry within the chosen market.
Top five reasons to order your copy today
-Gain insights into the competitive dynamics of specific emergent
pharma markets, using this report’s extensive qualitative and quantitative
analysis of external growth drivers, leading therapeutic areas, pricing
and reimbursement, and licensing trends.
-Discover the therapy areas with the greatest potential to stimulate
franchise growth within individual emergent markets, and learn how to
exploit these opportunities more effectively.
-Identify the key issues affecting both major pharma marketers and
the development of branded and generic products, by accessing the
latest competitive intelligence from across the emergent markets.
-Compare the healthcare systems and legislative developments of
24 emergent countries, and examine their impact upon pharma sales
within their respective markets.
-Evaluate the strategies and product portfolios of leading pharma
companies, and assess their responses to competitive change.
Product samples
Chapter 3 Regional Analysis Sample
Customers who bought this item also bought
Emerging Pharmaceutical Markets: Growth Opportunities, Changing Healthcare Dynamics and Regulatory Trends
General Dynamics Corporation - Company Profile, Financials and Condensed Data
Relationship Dynamics in Promotions Demand Management
Dynamics of the Korean Convergence Market in 2006
Cambodia PC & Server Market Dynamics
Pharmaceutical Growth Opportunities in Brazil, Russia, India and China: Healthcare Reform, Market Dynamics and Key Players
The Microsoft CRM Radars (Vendor Focus)
Pharmaceutical Growth Opportunities in the EU Accession States: Healthcare Reform, Market Dynamics and Key Players
|
|
|
|
